Lavipharm Management
Management criteria checks 1/4
Lavipharm's CEO is Telemaque Lavidas, appointed in Jan 2024, has a tenure of 1.33 years. directly owns 0.31% of the company’s shares, worth €412.04K. The average tenure of the management team and the board of directors is 1.3 years and 4 years respectively.
Key information
Telemaque Lavidas
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.3% |
| Management average tenure | 1.3yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
CEO
Telemaque Lavidas
Mr. Telemaque Jean Lavidas is Executive Board Member of Lavipharm S.A. from July 2021 and serves as its Chief Executive Officer since 2024. Mr. Lavidas serves as Managing Director of Laboratoires Lavipharm...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Board Member | 1.3yrs | no data | 0.31% € 412.0k | |
| Group CFO & Investor Relations Officer | 3.4yrs | no data | no data | |
| Chief Accountant | no data | no data | no data | |
| Director of Legal & Compliance and Corporate Secretary | 3.2yrs | no data | no data | |
| Director of Marketing & Sales CHC | no data | no data | no data | |
| Human Resources Director | no data | no data | no data | |
| Director of Business Development & Acquisitions | 1.3yrs | no data | no data | |
| Deputy CEO & Director | 1.3yrs | no data | 0.12% € 158.3k | |
| Head of Medical Affairs of Lavipharm Hellas | no data | no data | no data | |
| Chief Commercial Officer International | 1.3yrs | no data | no data |
Experienced Management: BXA0's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Board Member | 5.9yrs | no data | 0.31% € 412.0k | |
| Deputy CEO & Director | 1.3yrs | no data | 0.12% € 158.3k | |
| Chairman of the Board | 4yrs | no data | 0.0013% € 1.7k | |
| Vice President of the Board | no data | no data | 0.076% € 101.3k | |
| Non Executive Director | no data | no data | no data | |
| Independent Non Executive Director | no data | no data | no data | |
| Independent Non-Executive Board Member | 2.3yrs | no data | no data | |
| Independent Non Executive Director | 5.5yrs | no data | no data |
Experienced Board: BXA0's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/21 11:46 |
| End of Day Share Price | 2025/05/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lavipharm S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.